What should you know about INSM1 immunohistochemistry?

A pathologist applies an antibody stain to thin sections of tissue obtained during a biopsy or surgery. If the cells show the expected staining pattern, INSM1 can support the interpretation that they have neuroendocrine differentiation. The result is one part of a wider report, not a diagnosis in isolation.

The wording may describe staining as positive, negative, weak, strong, focal, or diffuse. These terms describe what was seen in the examined tissue. They need to be read alongside the tumour’s appearance under the microscope, other immunostains, imaging, and clinical information.

Ask the treating team to explain why INSM1 was ordered and which diagnosis the full panel supports. Request clarification of unfamiliar terms such as neuroendocrine differentiation, marker panel, or tissue adequacy. A biopsy is the usual source of tissue for this testing; the sample may be reviewed or additional stains may be requested when the findings do not give a clear answer.

Keep a copy of the pathology report and bring it to appointments with the oncologist, surgeon, or pathologist. Treatment decisions are based on the complete diagnosis, tumour location, extent, and the person’s overall health rather than on one stain alone.

Contact the clinical team promptly if you have a new pathology result and do not know what happens next, or if the report says the sample is limited or the findings are uncertain. Seek urgent medical help for severe breathing difficulty, new weakness, confusion, uncontrolled bleeding, or rapidly worsening symptoms; these problems need assessment regardless of the INSM1 result.

What diagnosis does the complete pathology panel support? Was INSM1 the only marker used? Does the report suggest neuroendocrine differentiation, and how certain is that interpretation? Is more tissue, a second pathology review, or another test needed? How will this result affect the next treatment or imaging decision?